top of page

NEW UPDATE: *Change in process for outpatient COVID-19 management*

To MUHC users: Please note that as of Dec 5, 2022, requests for outpatient antiviral management of COVID-19 for HIGH RISK patients should be directed to the ID-AMB (formerly MicroB/Lachine) service rather than ID-HOT. If a patient is a potential candidate for outpatient antiviral therapy but a delay is anticipated before they can be seen by Medical Day (eg. present to ED on a friday afternoon, weekend etc), please ensure that the antiviral is started in ED to ensure there are no delays in treatment! Prophylactic Evusheld should be offered to high-risk patients (see criteria) if > 6 months since their last dose.

36 views0 comments

Recent Posts

See All

S.aureus bacteremia

The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus aureus bacteremia. The diagnostic and antibiotic choice are di

Occupational exposure prophylaxy guidelines

ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on our website! Francois Bourdeau ASP MUHC coordinator

Update in COVID guidelines

The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar


bottom of page